Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/2/215 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588726786588672 |
|---|---|
| author | Kara I. Cicero Rahul Banerjee Mary Kwok Danai Dima Andrew J. Portuguese Delphine Chen Majid Chalian Andrew J. Cowan |
| author_facet | Kara I. Cicero Rahul Banerjee Mary Kwok Danai Dima Andrew J. Portuguese Delphine Chen Majid Chalian Andrew J. Cowan |
| author_sort | Kara I. Cicero |
| collection | DOAJ |
| description | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key goals for the management of myeloma precursor conditions include (1) identifying patients at the highest risk for progression to MM with bone involvement and (2) differentiating precursor states from active myeloma requiring treatment. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT with [<sup>18</sup>F]fluorodeoxyglucose (FDG) have improved sensitivity for the detection of myeloma bone disease compared to traditional skeletal surveys, and such advanced imaging also provides this field with better tools for detecting early signs of progression. Herein, we review the data supporting the use of advanced imaging for both diagnostics and prognostication in myeloma precursor conditions. |
| format | Article |
| id | doaj-art-cbd2f70318b647828ee590f9c5412889 |
| institution | Kabale University |
| issn | 2075-4418 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj-art-cbd2f70318b647828ee590f9c54128892025-01-24T13:29:08ZengMDPI AGDiagnostics2075-44182025-01-0115221510.3390/diagnostics15020215Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor ConditionsKara I. Cicero0Rahul Banerjee1Mary Kwok2Danai Dima3Andrew J. Portuguese4Delphine Chen5Majid Chalian6Andrew J. Cowan7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USADepartment of Radiology, University of Washington, Seattle, WA 98115, USADepartment of Radiology, University of Washington, Seattle, WA 98115, USAClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USAMonoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), the asymptomatic precursors to multiple myeloma, affect up to 5% of the population over the age of 40. Bone involvement, a myeloma-defining event, represents a major source of morbidity for patients. Key goals for the management of myeloma precursor conditions include (1) identifying patients at the highest risk for progression to MM with bone involvement and (2) differentiating precursor states from active myeloma requiring treatment. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)-CT with [<sup>18</sup>F]fluorodeoxyglucose (FDG) have improved sensitivity for the detection of myeloma bone disease compared to traditional skeletal surveys, and such advanced imaging also provides this field with better tools for detecting early signs of progression. Herein, we review the data supporting the use of advanced imaging for both diagnostics and prognostication in myeloma precursor conditions.https://www.mdpi.com/2075-4418/15/2/215multiple myelomasmoldering multiple myelomaMGUSimaging |
| spellingShingle | Kara I. Cicero Rahul Banerjee Mary Kwok Danai Dima Andrew J. Portuguese Delphine Chen Majid Chalian Andrew J. Cowan Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions Diagnostics multiple myeloma smoldering multiple myeloma MGUS imaging |
| title | Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions |
| title_full | Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions |
| title_fullStr | Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions |
| title_full_unstemmed | Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions |
| title_short | Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions |
| title_sort | illuminating the shadows innovation in advanced imaging techniques for myeloma precursor conditions |
| topic | multiple myeloma smoldering multiple myeloma MGUS imaging |
| url | https://www.mdpi.com/2075-4418/15/2/215 |
| work_keys_str_mv | AT karaicicero illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT rahulbanerjee illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT marykwok illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT danaidima illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT andrewjportuguese illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT delphinechen illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT majidchalian illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions AT andrewjcowan illuminatingtheshadowsinnovationinadvancedimagingtechniquesformyelomaprecursorconditions |